Focused ultrasound has moved from experimental curiosity to a genuine treatment option for Parkinson’s disease, with randomized trials now showing meaningful improvements in tremor, rigidity, and dyskinesia. The procedure uses MRI-guided sound waves to create a tiny, precise lesion deep in the brain without any incision, and several brain targets have been tested in clinical trials with follow-up data now stretching to five years. The picture that emerges is promising but layered: the treatment works well for specific symptoms, carries real risks, and is not yet a fit for every patient.
How the Procedure Works
The technology behind focused ultrasound for Parkinson’s relies on high-intensity sound waves converging on a single point inside the brain. A helmet-like transducer array, worn by the patient while they lie inside an MRI scanner, directs over a thousand ultrasound beams through the skull. Individually, each beam is harmless. Where they converge, though, the combined energy heats tissue enough to destroy it, a process called thermal ablation. At the focal point, temperatures climb high enough to cause cell death in a target roughly the size of a grain of rice.1Journal of Korean Neurosurgical Society. Magnetic Resonance-Guided Focused Ultrasound : Current Status and Future Perspectives in Thermal Ablation and Blood-Brain Barrier Opening The MRI provides real-time temperature monitoring, so clinicians can see exactly where the heat is building and adjust on the fly. Patients are awake during the procedure, which lets the team test each incremental sonication by checking whether tremor or rigidity improves before committing to a permanent lesion.
This approach grew out of decades of surgical evolution. Open craniotomy for movement disorders gave way to stereotactic techniques using probes inserted through a small skull opening, which in turn inspired non-destructive deep brain stimulation. Focused ultrasound represents the next step: achieving the same kind of targeted brain lesion without opening the skull at all.2PubMed Central. Evolution of Movement Disorders Surgery Leading to Contemporary Focused Ultrasound Therapy for Tremor
Treating Parkinsonian Tremor
The first and best-studied application of focused ultrasound in Parkinson’s targets the ventral intermediate nucleus of the thalamus, a relay station involved in tremor circuits. A randomized, sham-controlled trial in tremor-dominant Parkinson’s patients found that hand tremor scores improved by about 62% in the treated group compared with roughly 22% in the sham group, a statistically significant difference even accounting for the placebo response.3JAMA Neurology. Safety and Efficacy of Focused Ultrasound Thalamotomy for Patients With Medication-Refractory, Tremor-Dominant Parkinson Disease: A Randomized Clinical Trial Side effects in that trial included numbness around the mouth or fingers and, in two early cases, mild weakness from heat spreading to a nearby brain tract. Those issues improved, and the protocol was adjusted to prevent recurrence.
Longer-term data tell an encouraging story. A study following 26 tremor-dominant Parkinson’s patients for up to five years found that tremor was eliminated or nearly eliminated in the treated arm immediately after the procedure in all patients. Over time, tremor returned completely in two patients and partially in eight, but the group’s tremor and motor scores remained significantly better than baseline throughout follow-up, and side effects were mild and resolved within three months.4PubMed Central. Focused Ultrasound Thalamotomy in Tremor Dominant Parkinson’s Disease: Long-Term Results The takeaway: thalamotomy via focused ultrasound can provide durable tremor relief, but it is not always permanent, and some patients will see symptoms creep back over the years.
Going Beyond Tremor
Tremor is only one piece of Parkinson’s disease. Many patients are more troubled by rigidity, slowness of movement, or the involuntary writhing movements (dyskinesia) that develop as a side effect of long-term levodopa therapy. Researchers have pursued two additional brain targets to address these broader motor problems.
The Globus Pallidus
A pallidotomy, or lesion in the internal segment of the globus pallidus, has historically been used to treat dyskinesia. An early feasibility study of focused ultrasound pallidotomy showed a 59% improvement in dyskinesia scores at three months that held at about 43% improvement at one year. Motor signs on the treated side also improved by roughly 45% at one year.5PubMed. MR-guided focused ultrasound pallidotomy for Parkinson’s disease: safety and feasibility A larger randomized trial published in the New England Journal of Medicine confirmed the finding: about 69% of patients in the treatment group met the response threshold at three months, compared with 32% in the sham group. Of those who responded, most still met the criteria at twelve months.6PubMed. Trial of Globus Pallidus Focused Ultrasound Ablation in Parkinson’s Disease Side effects in the treatment group included speech changes, gait disturbance, and facial weakness.
The Subthalamic Nucleus
The subthalamic nucleus is the main target in deep brain stimulation surgery for Parkinson’s, and focused ultrasound can lesion it too. A randomized trial found that motor scores on the more affected side dropped by about half in the treatment group at four months, compared with a negligible change in the sham group.7PubMed. Randomized Trial of Focused Ultrasound Subthalamotomy for Parkinson’s Disease A separate prospective study reported improvements in rigidity of about 84%, bradykinesia of about 69%, and tremor of roughly 92% on the treated side at six months, and the degree of improvement correlated with how thoroughly the subthalamic nucleus was ablated.8PubMed Central. Unilateral Magnetic Resonance-Guided Focused Ultrasound Lesion of the Subthalamic Nucleus in Parkinson’s Disease: A Prospective Study Unlike thalamotomy for tremor alone, subthalamotomy addresses multiple motor features at once, making it attractive for patients whose problems extend well beyond tremor.
The trade-off is a more complex side-effect profile. In the randomized subthalamotomy trial, dyskinesia appeared in several patients, some developed gait disturbance or speech changes, and a small number still had persistent deficits at twelve months.7PubMed. Randomized Trial of Focused Ultrasound Subthalamotomy for Parkinson’s Disease These are the kinds of risks clinicians weigh carefully when choosing among targets.
How Long the Benefits Last
Because focused ultrasound creates a permanent lesion, the benefits do not simply switch off the way deep brain stimulation would if its battery died. But Parkinson’s disease itself is progressive, and new symptoms emerge on the untreated side over time. Five-year follow-up data from a subthalamotomy cohort showed that motor scores on the treated side remained about 54% better than baseline. The total motor score, including both sides, was still about 27% improved. Quality of life and functional disability, however, returned to roughly baseline levels by five years, reflecting progression of the disease on the untreated side and in non-motor domains.9PubMed. Five-Year Follow-Up of Unilateral Focused Ultrasound Subthalamotomy for Parkinson’s Disease
Three-year data from a separate group painted a similar picture. Motor scores on the treated side were still improved by about 52%, and all individual motor features, including tremor, rigidity, and bradykinesia, remained better than before the procedure. No delayed or disabling side effects appeared between the first year and year three.10PubMed Central. Prospective Long-term Follow-up of Focused Ultrasound Unilateral Subthalamotomy for Parkinson Disease The pattern across studies is fairly consistent: the treated side holds its gains well, but overall quality of life stabilizes rather than continuing to improve, because the procedure does not halt the underlying disease.
The Challenge of Treating Both Sides
Parkinson’s often affects both sides of the body, yet focused ultrasound procedures have mostly been performed on one brain hemisphere at a time. Bilateral lesions, treating both sides, have historically been considered risky in traditional surgery because damage to midline structures can cause permanent speech and swallowing problems. That concern carries over to focused ultrasound, but researchers have cautiously begun testing staged bilateral procedures, where the second side is treated months after the first.
A bilateral thalamotomy trial for essential tremor (a condition that overlaps with Parkinson’s tremor treatment) found that the vast majority of side effects were mild. At twelve months, some patients still had numbness, mild speech changes, or mild coordination problems, but severe complications were rare.11JAMA Neurology. Safety and Efficacy of Staged, Bilateral Focused Ultrasound Thalamotomy in Essential Tremor: An Open-Label Clinical Trial Staged bilateral subthalamotomy has also been attempted in Parkinson’s patients. In one series, four patients developed dyskinesia after the second treatment, but levodopa dose reductions resolved it in all cases within three months. Speech disturbances occurred in four patients; by six months, only mild residual issues remained, and none interfered with daily communication.12JAMA Neurology. Staged Bilateral MRI-Guided Focused Ultrasound Subthalamotomy for Parkinson Disease
A larger multicentre study of staged bilateral pallidothalamic tractotomy, a slightly different target, illustrated the cumulative risk more starkly. After unilateral treatment, about 39% of patients experienced treatment-related side effects, but only one had a persistent moderate problem at six months. After the second-side procedure, 55% had side effects, and a quarter still had moderate or severe problems at one year, mainly in speech, gait, and balance. One patient developed severe and persistent inability to speak.13The Lancet Neurology. Ultrasound for Parkinson’s: A New Treatment Option The authors concluded that while unilateral treatment showed clear benefit, bilateral procedures demand careful patient selection and frank discussions about the added risks.
Side Effects Across Studies
Focused ultrasound avoids the infection and bleeding risks that come with opening the skull, but it is not side-effect-free. A pooled analysis of 410 patients who underwent thalamotomy for tremor (including both Parkinson’s and essential tremor) found the most common problems were gait issues (about 37%), numbness or tingling in the hand (about 16%) or face (about 13%), taste disturbances (about 11%), weakness (about 6%), and coordination problems (about 5%). Most of these resolved, but roughly one in five patients still had at least one persistent side effect at their most recent follow-up.14PubMed Central. High Intensity Focused Ultrasound – Longitudinal Data on Efficacy and Safety
The nature of the side effects depends on the brain target. Thalamotomy tends to produce sensory symptoms like numbness and tingling. Subthalamotomy carries a higher risk of involuntary movements (dyskinesia) because the subthalamic nucleus is closely involved in regulating movement output. Pallidotomy can affect speech and gait. Across all targets, the risk profile is shaped by the millimeter-scale anatomy of the brain: heat spreading even slightly beyond the intended target can affect adjacent tracts that control speech, sensation, or balance.
Who Qualifies for the Procedure
Not everyone with Parkinson’s is a candidate. The procedure requires that ultrasound energy pass efficiently through the skull, and skulls vary a lot in their acoustic properties. Skull density ratio, a measure derived from CT scans, is used to predict whether enough energy can reach the target to create a therapeutic lesion. One study found that skull volume was negatively correlated with the maximum temperature achievable at the target, while skull density ratio was positively correlated, meaning patients with larger or less dense skulls may have a harder time reaching therapeutic temperatures.15Journal of Neurosurgery. Factors associated with successful magnetic resonance-guided focused ultrasound treatment: efficiency of acoustic energy delivery through the skull
Roughly half of tremor patients evaluated for focused ultrasound thalamotomy meet the skull-based eligibility criteria, and about 20% of patients fall into a range where achieving therapeutic temperatures becomes empirically difficult.16PubMed Central. The Distribution of Skull Score and Skull Density Ratio in Tremor Patients for MR-Guided Focused Ultrasound Thalamotomy That said, a low skull density ratio is not always a deal-breaker. One study found that patients with a ratio below the traditional threshold still achieved successful thalamotomy lesions, though they required more energy to get there.17PubMed. The relevance of skull density ratio in selecting candidates for transcranial MR-guided focused ultrasound Clinicians are still refining the cutoffs, and the technology continues to improve, but skull characteristics remain the single biggest anatomical gate that determines whether a patient can undergo the procedure.
Beyond skull properties, clinical selection matters too. Patients generally need to have medication-refractory symptoms on at least one side, be in reasonable overall health, and be able to lie still in an MRI scanner for several hours. Cognitive impairment can be a disqualifier, particularly for subthalamotomy, where the risk-benefit calculus requires a patient who can cooperate with intraoperative testing and tolerate the potential for postoperative speech changes.
How Focused Ultrasound Compares to Deep Brain Stimulation
Deep brain stimulation (DBS) has been the surgical standard of care for Parkinson’s for over two decades. It involves implanting electrodes into the brain and connecting them to a battery-powered stimulator under the collarbone. The stimulation is adjustable and reversible: if settings are wrong or the patient’s needs change, the device can be reprogrammed. Focused ultrasound, by contrast, creates a permanent lesion and cannot be adjusted after the fact.
A network meta-analysis comparing the two approaches found that focused ultrasound subthalamotomy ranked highest for motor score improvement in both the on- and off-medication states, ahead of DBS targeting either the subthalamic nucleus or the globus pallidus. However, for quality of life, DBS targeting the globus pallidus ranked first, followed by subthalamic DBS, with focused ultrasound subthalamotomy ranking third.18Frontiers in Neurology. Ameliorating motor performance and quality of life in Parkinson’s disease: a comparison of deep brain stimulation and focused ultrasound surgery That gap in quality-of-life rankings likely reflects the fact that DBS treats both sides of the body (bilateral electrodes are standard), while most focused ultrasound data come from unilateral procedures. It also reflects DBS’s adjustability: if a patient develops speech trouble, stimulation parameters can be dialed back. With a lesion, there is no undo button.
Where focused ultrasound has clear practical advantages: it requires no implanted hardware, no general anesthesia, no incision, and no follow-up visits for device programming. There is no risk of device infection or lead migration. For patients who cannot or do not want to undergo an implant procedure, or who live far from a programming center, focused ultrasound is a compelling alternative. A cost-effectiveness analysis found that focused ultrasound thalamotomy was cost-effective compared with continued medical therapy for tremor-dominant Parkinson’s and remained competitive with DBS, though the cost advantage over DBS was less pronounced.19PubMed. Cost-effectiveness analysis of MR-guided focused ultrasound thalamotomy for tremor-dominant Parkinson’s disease
Opening the Blood-Brain Barrier
All of the applications discussed so far use high-intensity ultrasound to destroy tissue. But researchers are also exploring a fundamentally different use: low-intensity focused ultrasound combined with injected microbubbles to temporarily open the blood-brain barrier. The blood-brain barrier normally prevents most drugs from reaching the brain, which is one of the central challenges in treating neurodegenerative diseases. When low-intensity ultrasound hits the microbubbles circulating in the bloodstream, they vibrate and gently stretch the tight junctions between cells lining the brain’s blood vessels, creating a window of a few hours during which drugs or antibodies can pass through.20PubMed. Ultrasound-induced blood-brain barrier opening for drug delivery
This approach is being studied for its potential to deliver therapies that target alpha-synuclein, the protein that misfolds and clumps in the brains of Parkinson’s patients. Animal studies and early human work suggest that focused ultrasound can enable passage of therapeutic agents into specific brain regions, and that it may also help clear toxic proteins through enhanced drainage pathways.21PubMed Central. Characteristics of Focused Ultrasound Mediated Blood-Brain Barrier Opening in Magnetic Resonance Images A review of low-intensity focused ultrasound in Parkinson’s describes two major pathways under investigation: direct modulation of brain circuits and blood-brain barrier opening for targeted drug delivery, with preclinical evidence for effects on alpha-synuclein aggregation, neuroinflammation, and neurotrophic signaling.22PubMed. Application of Low-Intensity Focused Ultrasound in Parkinson’s Disease This research is still early-stage, but it represents a potential shift from treating Parkinson’s symptoms to modifying the disease itself.
Low-Intensity Ultrasound as Reversible Neuromodulation
There is a third mode of ultrasound therapy that sits between destroying tissue and opening the blood-brain barrier: using low-intensity focused ultrasound to temporarily excite or suppress neural activity without creating a lesion. This works somewhat like a non-invasive, temporary version of deep brain stimulation. The ultrasound energy is too low to heat tissue to destructive levels but strong enough to mechanically influence neuron membranes and alter firing patterns. The effect wears off, making it inherently reversible.23PubMed Central. A review of low-intensity focused ultrasound for neuromodulation
For Parkinson’s, this is appealing because it could allow clinicians to test whether modulating a specific brain target helps a patient before committing to a permanent lesion or an implanted device. It could also, in theory, be repeated as a chronic treatment, though the practicality of regular MRI-guided sessions is a hurdle. The research here is less mature than for ablative procedures, with most evidence still coming from animal models and small proof-of-concept studies. But the ability to precisely target deep brain structures without surgery, implants, or permanent changes makes it one of the more watched areas in movement disorder research.